Selection of a set of digital endpoints and corresponding digital devices/technologies for the evaluation of fatigue and sleep disturbances for clinical validation, and to explore digital correlates of other ADLs by profiling activity, biological, neurocognitive and behavioural aspects in patients with IBD, RA, SLE, PSS, PD and HD.

Implementation of a robust, seamless, interoperable and secure digital management platform that is compliant with legal and data privacy requirements to support data acquisition, storage, analysis of patient and professional information; and to define standards for data integration, analysis, storage and sharing (including secondary use of data to maximise impact and exploitation).

Establishing a large and well-characterised longitudinal cohort of IBD, RA, SLE, PSS, PD and HD patients with detailed records about the candidate digital endpoints described in objective 1.

Evaluating the clinical validity of the candidate digital endpoints compared to gold standards, and to seek qualification advice of their use as novel digital endpoints by the EMA and FDA, and to obtain opinion about the role of these endpoints in supporting health utility evaluation by Health Technology Agencies (HTA).

Ensuring lasting impact through the creation of a properly annotated database compatible with the International Classification of Functioning, Disability, and Health (ICF) which will include real-world digital datasets of biophysiological, neurocognitive, behavioural, personal, environmental and socialization observations coupled with comprehensive clinical data to support the possible finalization of the regulatory qualification process to foster future academic and industrial studies aimed to develop novel treatments.